-
Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity
– Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis – – Reported In Vitro Data Showing That IMU-935 May Inhibit the Generation of Th17 Cells and Production of IL-17 Cytokines Without Impairing RORγt Function Required for Normal Thymocyte Development – – Reported Preclinical Data Establishing IMU-935 as a Potential Treatment for Castration-Resistant Prostate Cancer; Preparing for a Phase 1 Clinical Trial – – $87.2 Million in Cash and Cash Equivalents as of June 30, 2021 and the Additional $45.0 Million Raised in July are Expected to Fund Immunic Into 2023 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company…
-
Immunic, Inc. Announces Closing of $45.0 Million Public Offering
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10.00 per share. The Company received total proceeds from the offering, before deducting the underwriting discounts and other offering expenses, of $45.0 million. Piper Sandler acted as sole book-runner for the offering. Ladenburg Thalmann & Co. Inc., Roth Capital Partners and Aegis Capital Corp. acted as co-managers for the offering. The Company intends to use the net proceeds of the offering to fund…
-
Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10 per share. The gross proceeds of the offering to the Company are expected to be approximately $45 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price. The closing of the offering…
-
Immunic, Inc. Announces Proposed Public Offering of Common Stock
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All the shares to be sold in the offering will be offered by the Company. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase…
-
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
. – Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval – Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis (PMS), Designed to Corroborate IMU-838’s Neuroprotective Potential and Support Differentiated Profile – Company Expects Initiation of Both ENSURE and CALLIPER in the Second Half of 2021 – Conference Call and Webcast to be Held July 1, 2021 at 8:00 am ET Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced U.S. Food and Drug…
-
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic. "Inderpal is a seasoned legal executive, having spent 20 years in-house, advising several of the world’s largest life sciences companies. As such, he brings to Immunic extensive legal knowledge related to clinical development, operations, regulatory affairs, and commercialization," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "We welcome Inderpal…
-
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2021 and highlighted recent activity. "Our clinical program activities have continued unabated, with significant progress having recently been achieved for our lead asset, selective oral DHODH inhibitor, IMU-838," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "Last month, we announced key interim data from our phase 2 EMPhASIS Cohort 2 sub-trial of IMU-838 in patients with relapsing-remitting multiple sclerosis (RRMS), confirming 30 mg as the most appropriate dose for our envisaged phase 3 program. We…
-
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838
Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the signing of an agreement under which Immunic will settle its remaining obligation of a 4.4% royalty on net sales of selective oral DHODH inhibitor, IMU-838, for $17.25 million. The transaction will be payable 50% in cash and 50% in shares of Immunic’s common stock. Immunic acquired lead program IMU-838 in September 2016 from 4SC AG through an asset acquisition, in exchange for a one-time upfront cash payment, future milestone payments and a royalty on net sales for…
-
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021 Reported Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis Announced Main Analysis of Phase 2 CALVID-1 Trial of IMU-838 Showing Evidence of Clinical Activity in Patients with Moderate COVID-19 Significantly Bolstered Balance Sheet, Raising Approximately $144.4 Million of Cash During 2020 With $127.5 Million in Cash and Cash Equivalents, Immunic is Funded Into the Second Half of 2022 Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced financial results…
-
Immunic, Inc. Added to NASDAQ Biotechnology Index
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market…
